Resistance Mutations and CTL Epitopes in Archived HIV-1 DNA of Patients on Antiviral Treatment: Toward a New Concept of Vaccine

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Papuchon, Jennifer ^a   Pinson, Patricia ^a   Lazaro, Estibaliz ^b   Reigadas, Sandrine ^a   Guidicelli, Gwendaline ^a   Taupin, Jean Luc ^a   Neau, Didier ^a   Fleury, Hervé ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN; GAG PROTEIN; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; LIPOPEPTIDE; LYMPHOCYTE ANTIGEN; NEF PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; DRUG RESISTANCE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; MOLECULAR TYPING; MUTATION; NUCLEOTIDE SEQUENCE; PYROSEQUENCING; STOP CODON; VACCINATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

AIDS VACCINES; ALLELES; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EPITOPES, T-LYMPHOCYTE; GENES, MHC CLASS I; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879959110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069029     Document Type: Article

References (19)

1. Deeks S, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614.
2. Eisele E, Siliciano RF, (2012) Redefining the Viral Reservoirs that Prevent HIV-1 Eradication. Immunity 37: 377-388.
3. McMichael AJ, Rowland-Jones SL, (2001) Cellular immune responses to HIV. Nature 410: 980-987.
4. Liu Y, McNevin JP, Holte S, McElrath MJ, Mullins JI, (2011) Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS One 6: e15639.
5. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208.
6. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 458: 641-645.
7. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443.
8. Carrington M, O'Brien SJ, (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 535-551.
9. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, et al. (2012) Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol 86: 5230-5243.
10. Brumme ZL, Chopera DR, Brockman MA, (2012) Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Curr Opin Virol 2: 599-605.
11. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
12. Recordon-Pinson P, Papuchon J, Reigadas S, Deshpande A, Fleury H, (2012) K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data. PLoS One 7: e36549.
13. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105: 3879-3884.
14. Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, et al. (2010) Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 24: 2211-2223.
15. Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, et al. (2008) Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol 15: 562-568.
16. Palmisano L, Giuliano M, Galluzzo CM, Amici R, Andreotti M, et al. (2009) The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Med 10: 477-481.
17. Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, et al. (2012) The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26: 1885-1894.
18. Queen SE, Mears BM, Kelly KM, Dorsey JL, Liao Z, et al. (2011) Replication-competent Simian Immunodeficiency Virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol 85: 9167-9175.
19. García F, León A, Gatell JM, Plana M, Gallart T, (2012) Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 8: 569-581.